Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Oct 21 2013

Cytos Biotechnology Ltd (SIX:CYTN) ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003. This study investigates the effectiveness, safety and tolerability of CYT003 in patients with moderate to severe allergic asthma not controlled on their standard treatment.

Based on the completion of the enrolment of this study, Cytos will call the second tranche of the convertible loan notes in the amount of CHF 6.625 million from Abingworth, venBio, Aisling and Amgen, which was part of the investment by this syndicate of investors in May 2012.

Dr. Christian Itin, Chairman and CEO of Cytos, said: "We are pleased with the progress of our Phase 2b study in patients with moderate to severe allergic asthma. The study is on track and we expect topline data from the study to be available in the second quarter of 2014."

Source:

Cytos Biotechnology Ltd

Posted in: Drug Trial News | Medical Condition News

Comments (0)

Suggested Reading

Asthma-related emergency visits increase during wildfire smoke events in Ontario
Study links air pollution, urban development and lack of green spaces to asthma
Progesterone-only contraceptive pill linked to increased asthma attacks in some women
Best time for asthma meds? Try 4 pm
Exploring how type 2 inflammation influences heart health and asthma
Air pollution exposure in pregnancy may increase asthma risk for the next generation
Tomato and fruit juice improve quality of life for kids with asthma
Afternoon could be best time for asthma inhaler, study shows

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Asthma drug once hoped to treat alcohol use disorder fails to meet expectations in UCLA trial